Polymyxins: A new hope in combating Gram-negative superbugs?

Future Medicinal Chemistry

Volumn 8, Issue 10, 2016, Pages 1017-1025

  Velkov, Tony ^a   Roberts, Kade D ^a   Thompson, Philip E ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Drug discovery; Nephrotoxicity; Polymyxins; Resistance

Indexed keywords

CB 182804; COLISTIN; NAB 7061; NAB 739; NAB 741; POLYMYXIN; POLYMYXIN B; POLYMYXIN B NONAPEPTIDE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; DRUG DESIGN; GRAM NEGATIVE BACTERIUM; HYDROPHOBICITY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PAENIBACILLUS POLYMYXA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMAN; MEDICINAL CHEMISTRY; MULTIDRUG RESISTANCE;

ANIMALS; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; POLYMYXINS;

EID: 84977103552     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc-2016-0091     Document Type: Review

References (47)

1. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T 40(4), 277-283 (2015).
2. Shlaes DM. Antibiotics: The Perfect Storm conclusions. In: Antibiotics: The Perfect Storm. Springer, The Netherlands, 97-99 (2010).
3. Shlaes DM, Spellberg B. Overcoming the challenges to developing new antibiotics. Curr. Opin. Pharmacol. 12(5), 522-526 (2012).
4. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States (2013). www. cdc. gov/drugresistance/pdf/ar-threats-2013-508. pdf
5. Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int. J. Antimicrob. Agents 32(5), 450-454 (2008).
6. Antoniadou A, Kontopidou F, Poulakou G et al. Colistinresistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J. Antimicrob. Chemother. 59(4), 786-790 (2007).
7. Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: The dawn of the post-antibiotic era? Int. J. Antimicrob. Agents 29(6), 630-636 (2007).
8. Valencia R, Arroyo LA, Conde M et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect. Control. Hosp. Epidemiol. 30(3), 257-263 (2009).
9. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gramnegative bacteria. Ann. Pharmacother. 33(9), 960-967 (1999).
10. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40(9), 1333-1341 (2005).
11. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin. Microbiol. Rev. 21(3), 449-465 (2008).
12. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review. J. Antimicrob. Chemother. 60, 1206-1215 (2007).
13. Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiol. 8(6), 711-724 (2013).
14. Liu YY, Wang Y, Walsh TR et al. Emergence of plasmidmediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. Lancet Infect. Dis. 16(2), 161-168 (2016).
15. Webb HE, Granier SA, Marault M et al. Dissemination of the MCR-1 colistin resistance gene. Lancet Infect. Dis. 16(2), 144-145 (2016).
16. Choi SK, Park SY, Kim R et al. Identification of a polymyxin synthetase gene cluster of Paenibacillus polymyxa and heterologous expression of the gene in Bacillus subtilis. J. Bacteriol. 191(10), 3350-3358 (2009).
17. Velkov T, Thompson PE, Nation RL, Li J. Structure-activity relationships of polymyxin antibiotics. J. Med. Chem. 53(5), 1898-1916 (2010).
18. Clausell A, Garcia-Subirats M, Pujol M, Busquets MA, Rabanal F, Cajal Y. Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides. J. Phys. Chem. B Condens. Matter Surf. Interfaces Biophys. 111(3), 551-563 (2007).
19. Ofek I, Cohen S, Rahmani R et al. Antibacterial synergism of polymyxin B nonapeptide and hydrophobic antibiotics in experimental gram-negative infections in mice. Antimicrob. Agents Chemother. 38(2), 374-377 (1994).
20. Helander IM, Kilpelainen I, Vaara M. Increased substitution of phosphate groups in lipopolysaccharides and lipid A of the polymyxin-resistant pmrA mutants of Salmonella typhimurium: A 31P-NMR study. Mol. Microbiol. 11(3), 481-487 (1994).
21. Moskowitz SM, Ernst RK, Miller SI. PmrAB, a twocomponent regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J. Bacteriol. 186(2), 575-579 (2004).
22. Helander IM, Kato Y, Kilpeläinen I et al. Characterization of lipopolysaccharides of polymyxin-resistant and polymyxinsensitive Klebsiella pneumoniae O3. Eur. J. Biochem. 237(1), 272-278 (1996).
23. Clements A, Tull D, Jenney AW et al. Secondary acylation of Klebsiella pneumoniae lipopolysaccharide contributes to sensitivity to antibacterial peptides. J. Biol. Chem. 282(21), 15569-15577 (2007).
24. Perez JC, Groisman EA. Acid pH activation of the PmrA/PmrB two-component regulatory system of Salmonella enterica. Mol. Microbiol. 63(1), 283-293 (2007).
25. Adams MD, Nickel GC, Bajaksouzian S et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53(9), 3628-3634 (2009).
26. Beceiro A, Llobet E, Aranda J et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the PmrAB two-component regulatory system. Antimicrob. Agents Chemother. 55(7), 3370-3379 (2011).
27. Fernandez L, Gooderham WJ, Bains M, McPhee JB, Wiegand I, Hancock RE. Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the nnovel two-component regulatory system ParR-ParS. Antimicrob. Agents Chemother. 54(8), 3372-3382 (2011).
28. Chen JM. Polymyxin derivatives useful as antibacterial agents. Pfizer Inc, US, 2012: WO 2012/168820 A1.
29. Leese RA. Antibiotic composition for the treatment of Gramnegative infections. Biosource Pharm, Inc., U. S, 2010: US 2010/0160215 A1.
30. Magee TV, Brown MF, Starr JS et al. Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections. J. Med. Chem. 56, 5079-5093 (2013).
31. Saadi M, Duperchy E, Brown P, Dawson MJ, Wadman SN. Polymyxin Derivatives US, 2013: WO 2013/072695 A1.
32. Keith DD, Borders D, Curran W et al. Poster F1-1619 synthesis and activity of CB-182, 804, a novel polymyxin analog active against clinically relevant Gram-negative bacteria. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, MA, USA, 12-15 September 2010.
33. Brown P, Dawson M, Simonvic M, Boakes S, Duperchy E. Polymyxin derivatives and their use in combination therapy together with different antibiotics: WO 2014/188178 A1 (2014).
34. Brown P, Dawson M, Simonvic M et al. Polymyxin derivatives and their use in combination therapy together with different antibiotics: WO2015/135967 A1 (2015).
35. Ali FE, Cao G, Poudyal A et al. Pharmacokinetics of novel antimicrobial cationic peptides NAB 7061 and NAB 739 in rats following intravenous administration. J. Antimicrob. Chemother. 64(5), 1067-1070 (2009).
36. Vaara M. Novel derivatives of polymyxins. J. Antimicrob. Chemother. 68(6), 1213-1219 (2013).
37. Vaara M, Fox J, Loidl G et al. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob. Agents Chemother. 52(9), 3229-3236 (2008).
38. Vaara M, Sader HS, Rhomberg PR, Jones RN, Vaara T. Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. J. Antimicrob. Chemother. 68(3), 636-639 (2013).
39. Vaara M, Siikanen O, Apajalahti J et al. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob. Agents Chemother. 54(8), 3341-3346 (2010).
40. Vaara M, Siikanen O, Apajalahti J, Frimodt-Moller N, Vaara T. Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin. J. Antimicrob. Chemother. 65(5), 942-945 (2010).
41. Vaara M, Vaara T. The novel polymyxin derivative NAB739 is remarkably less cytotoxic than polymyxin B and colistin to human kidney proximal tubular cells. Int. J. Antimicrob. Agents 41(3), 292-293 (2013).
42. Vingsbo Lundberg C, Vaara T, Frimodt-Moller N, Vaara M. Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice. J. Antimicrob. Chemother. 65(5), 981-985 (2010).
43. Gallardo-Godoy A, Muldoon C, Becker B et al. Activity and predicted nephrotoxicity of synthetic antibiotics based on polymyxin B. J. Med. Chem. 59(3), 1068-1077 (2016).
44. Velkov T, Roberts KD, Nation RL, Wang J, Thompson PE, Li J. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'. ACS Chem. Biol. 9(5), 1172-1177 (2014).
45. Li J, Nation RL, Velkov T, Thompson PE, Roberts KD. Polymyxin derivatives as antimicrobial compounds. Monash University, 2015: WO 2015/149131 A1.
46. Huang JX, Blaskovich MA, Cooper MA. Cell-and biomarker-based assays for predicting nephrotoxicity. Expert Opin. Drug Metab. Toxicol. 10(12), 1621-1635 (2014).
47. Roberts KD, Azad MAK, Wang J et al. Antimicrobial activity and toxicity of the major lipopeptide components of polymyxin B and colistin: last-line antibiotics against multidrug-resistant Gram-negative bacteria. ACS Infect. Dis. 1(11), 568-575 (2016).